Дифференцированное применение антиагрегантов при лечении ишемической болезни сердца

1. Рекомендации по рациональной фармакотерапии сердечно-сосудистых заболеваний. Всероссийское научное общество кардиологов. Москва, 2009.
2. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Lewis A. Conner Memorial Lecture. Circulation 1994; 90 (4): 2126–46.
3. Белоусов Д.Ю., Медников О.И. Потребность и потребление антитромбоцитарных препаратов у постинфарктных больных в РФ. Качественная клиническая практика. 2003; 1: 60–70.
4. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
5. Kushner FJ et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Circulation 2009; 120: 2271–306.
6. Ушкалова Е.А. Аспиринорезистентность: механизмы развития, методы определения и клиническое значение. Фарматека 2006; 13: 35–41.
7. Snoep JD, Hovens MC, Eikenboom JCJ et al. Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events A Systematic Review and Meta-analysis. Arch Intern Med 2007; 167 (15): 1593–9.
8. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–31.
9. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374 (9694): 989–97.
10. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–20.
11. Hass WK, Easton JD, Adams HPJ. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321: 501–07.
12. Vivekananthan DP, Bhatt DL, Chew DP et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358–60.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39.
14. Patti G, Colonna G, Pasceri V et al. Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention.Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005; 11.
15. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. JAMA 2005; 294: 1224–32.
16. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21: 2033–41.
17. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366 (9497): 1607–21.
18. Vlaar PJ, Svilaas T, Damman K et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review. Circulation 2008; 118: 1828–36.
19. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706–17.
20. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363–75.
21. Ho PM, Maddox TM, Wang L et al. Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. JAMA 2009; 301 (9): 937–44.

Т.Е.Морозова, Т.Б.Андрущишина, О.А.Вартанова